| |
|
Therapeutic
Antibodies
|
|
| Cat No. |
|
Product Name |
Information |
| A2001 |
|
Ipilimumab |
Ipilimumab is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD. |
| A2005 |
|
Pembrolizumab |
Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD. |
| A2010 |
|
Adalimumab |
Adalimumab is the first fully human, recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha, MW: 144.19 KD. |
| A2006 |
|
Bevacizumab |
Bevacizumab is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD. |
| A2007 |
|
Trastuzumab |
Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD. |
| A2008 |
|
Pertuzumab |
Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD. |
| A2009 |
|
Rituximab |
Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD. |
| A2011 |
|
Sarilumab |
Sarilumab is a fully human anti-IL-6Rα mAb that binds membrane-bound and soluble human IL-6Rα with high affinity, MW: 144.13 KD. |
| A2012 |
|
Tocilizumab |
Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD. |
| A2002 |
|
Nivolumab |
Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD. |
| A2004 |
|
Atezolizumab |
Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD. |
| A2000 |
|
Cetuximab |
Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD. |
PI3K/Akt/mTOR
|
|
| Cat No. |
|
Product Name |
Information |
| S8672 |
|
Tenalisib (RP6530) |
Tenalisib (RP6530) is a potent and selective dual PI3Kδ/γ inhibitor with IC50 values of 24.5 nM and 33.2 nM for PI3Kδ and PI3Kγ, respectively. Its selectivity over α and β isoforms are more than 300-fold and 100-fold, respectively. |
JAK/STAT
|
|
| Cat No. |
|
Product Name |
Information |
| S8685 |
|
AS1517499 |
AS1517499 is a novel and potent STAT6 inhibitor with an IC50 value of 21 nM. |
Metabolism
|
|
| Cat No. |
|
Product Name |
Information |
| S4825 |
|
Pancreatin |
Pancreatic enzymes also known as pancrelipase and pancreatin, are commercial mixtures of amylase, lipase, and protease. They are used to treat malabsorption syndrome due to pancreatic problems. |
| S4871 |
|
Pyridoxal 5-phosphate monohydrate |
Pyridoxal 5-phosphate monohydrate is an active vitamin B6 metabolite, which is a cofactor in many reactions of amino acid metabolism. |
Microbiology
|
|
| Cat No. |
|
Product Name |
Information |
| S4971 |
|
Buparvaquone |
Buparvaquone is a second-generation hydroxynaphthoquinone related to parvaquone, with novel features that make it a promising compound for the therapy and prophylaxis of all forms of theileriosis. |
| S4978 |
|
Azathramycin |
Azathramycin (Azaerythromycin) is a macrolide antibiotic containing cladinose. |
| S5033 |
|
Terconazole |
Terconazole is a new, broad-spectrum, triazole antifungal agent which is primarily used to treat vaginal fungal infections. |
| S4866 |
|
Nicarbazin |
